POLYOXIDONIUM 6 mg/ml 5 vials - immunocorrector with anti-inflammatory action

POLYOXIDONIUM (azoximer bromide) helps suppress the progression of acute respiratory viral infections and influenza, supporting improved well-being from the first day of administration through its activity at viral entry sites and its assistance in eliminating viral toxins.

Polyoxidonium® contains the active substance azoximer bromide, classified as an immunostimulatory agent.

Indications:

Treatment and prevention of acute and chronic respiratory disorders:

• Acute respiratory viral infections (ARVI) and influenza
  Inflammatory diseases of the oropharynx, paranasal sinuses, upper and lower respiratory tract, as well as the inner and middle ear
• Allergic conditions (including hay fever and bronchial asthma) complicated by recurrent bacterial, fungal, and viral infections
• Exacerbations of chronic diseases of the upper respiratory tract, paranasal sinuses, and chronic otitis

Key properties:

• Stimulates early anti-infective immune defense by enhancing the activity of phagocytes, neutrophils, and NK cells, helping the body respond more effectively to viral infections.
• Provides detoxifying support by binding and assisting in the removal of toxins and inflammatory by-products, helping reduce symptoms of viral intoxication.
• When used topically, it acts directly on mucosal surfaces at the site of infection, activating local immune protection and helping prevent further viral spread.
• Supports regulation of inflammatory responses by balancing pro-inflammatory and anti-inflammatory cytokine production.
• Does not cause local irritation and is generally well tolerated.
• Included in the updated 2025 clinical recommendations of the Russian Ministry of Health for the treatment of acute respiratory viral infections and influenza in adults.
• Included in the list of vital and essential medicinal products.
• Sublingual tablets act directly on mucosal membranes at the primary site of viral penetration.

Action:

• Polyoxidonium® stimulates immune system activity and promotes the production of endogenous interferons — proteins naturally synthesized by the body in response to viruses and other pathogens — helping increase resistance to viral and bacterial infections.
• Polyoxidonium® binds soluble toxic compounds and microparticles, supports the elimination of toxins and heavy metal salts, and inhibits lipid peroxidation.
• Polyoxidonium® helps maintain the balance between pro-inflammatory and anti-inflammatory immune responses.

Composition:

Active ingredient: azoximer bromide - 6 mg/ml;
Other excipients: mannitol, povidone, water for injection.

Recommended treatment regimens:

For parenteral administration (intramuscular or intravenous): adults are prescribed 6–12 mg once daily, every other day, or 1–2 times weekly, depending on the diagnosis and severity of the condition.

The total volume of the preparation is calculated at a dose of 1 drop (0.3 mg) per 2 kg of body weight.

TREATMENT FOR ADULTS OVER 18 YEARS OF AGE (PARENTERAL — INTRAMUSCULAR OR INTRAVENOUS)

• For acute viral and bacterial infections of the ENT organs, upper and lower respiratory tract, gynecological, and urological diseases: 6 mg daily for 3 days, followed by administration every other day. Course: 10 injections.
• For generalized surgical infections: 6 mg daily for 3 days, then every other day. Course: 10 injections.
• To stimulate regenerative processes (fractures, burns, trophic ulcers): 6 mg daily for 3 days, then every other day. Course: 10 injections.
• For rheumatoid arthritis complicated by bacterial, viral, or fungal infections associated with prolonged immunosuppressive therapy: 6 mg every other day for 5 injections, then twice weekly for 10 injections; alternatively, 6–12 mg every other day for 5 injections.
• For prevention of postoperative infectious complications: 6 mg every other day for 5 injections.
• For pulmonary tuberculosis: 6 mg twice weekly for 20 injections.
• For oncology patients before and during chemotherapy to help reduce immunosuppressive, hepatotoxic, and nephrotoxic effects of chemotherapeutic agents: 6 mg every other day for 10 injections. Further administration frequency is determined individually by the physician according to tolerance and duration of chemotherapy or radiation therapy.
• For oncology patients to help prevent tumor-associated immunosuppression, correct immunodeficiency after chemotherapy or radiation therapy, and following surgical tumor removal: 6 mg 1–2 times weekly for prolonged use (2–3 months up to 1 year).
  No cumulative toxicity, dependence, or tolerance has been observed during long-term administration.

TREATMENT FOR ADULTS OVER 18 YEARS OF AGE (INTRANASAL OR SUBLINGUAL ADMINISTRATION)

• Treatment of acute and exacerbated chronic ENT infections: total daily dose — 1 ml (20 drops, 6 mg); administered intranasally or sublingually in 2–3 divided doses.
• Treatment and prevention of influenza and acute respiratory viral infections: total daily dose — 1 ml (20 drops, 6 mg); administered intranasally or sublingually in 2–3 divided doses.
• Support of regenerative processes in mucous membranes: total daily dose — 1 ml (20 drops, 6 mg); administered intranasally or sublingually in 2–3 divided doses.
• Prevention of complications and relapses of chronic diseases: total daily dose — 1 ml (20 drops, 6 mg); administered intranasally or sublingually in 2–3 divided doses.

Dosage form:

Solution for injection and topical use. 5 vials, 6 mg/ml. The preparation is supplied in 1.0 ml colorless glass vials, 5 vials in a blister pack, with 1 blister pack in a cardboard carton together with package instructions; alternatively, in 5.0 ml colorless glass vials, 1 vial per carton with a dropper nozzle and package insert.

Storage conditions:

Keep out of the reach and sight of children.

Do not use after the expiration date indicated on the packaging following the words “Best before”.

The expiration date refers to the last day of the specified month.

Store refrigerated at 2 to 8 °C.

Guaranteed authenticity and quality:

100% Original from PETROVAX PHARM (Russian Federation)

PETROVAX PHARM is a pharmaceutical manufacturer specializing in innovative biopharmaceutical products.

The company focuses on developing vaccines and medications for the prevention and treatment of infectious diseases, oncology conditions, and rare disorders.

Its portfolio includes proprietary medicines and vaccines, contract manufacturing services, and dietary supplements.

Modern research and development facilities. Petrovax Pharm holds Russian and international patents for proprietary molecules and manufacturing technologies.

Advanced full-cycle pharmaceutical manufacturing compliant with EAEU and EU GMP quality standards.

More than 30 years of pharmaceutical industry experience.

Development and production:

PETROVAX PHARM